Clinical trials
Peripheral Blood Stem Cell Transplantation clinical trials
Below are recruiting peripheral blood stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05674539Enrolling by invitationPhase 3
Less intense transplant regimen for AML or MDS patients
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
Wuhan, HubeiAges 18 years+ - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT04628026RecruitingPhase 3
Venetoclax plus chemotherapy for new AML or high-risk MDS
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
InnsbruckAges 18–75 - NCT04180059RecruitingPhase 1
Anti-DP treatment after stem cell transplant to prevent relapse
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
NantesAges 18–75 - NCT03909412RecruitingPhase 1
Carfilzomib chemo to help you collect stem cells for transplant
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
Hackensack, New JerseyAges 18 years+ - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT01861106RecruitingPhase 2
Bone marrow transplant for GATA2 mutations
This trial tests a bone marrow transplant (called allogeneic hematopoietic stem cell transplant) as a treatment for people with GATA2 mutations or MonoMAC. The goal is to replace faulty immune cells with healthy donor cells, which may reduce infections and improve immune function.
Bethesda, MarylandAges 6–70 - NCT04512534RecruitingPhase 2
Check-in study of immunotherapy plus another drug for lymphoma
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02356653RecruitingEarly Phase 1
Stem cell transplant help for children lacking a matching sibling
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Philadelphia, PennsylvaniaAges Up to 30 years - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT05182957RecruitingPhase 2
Study of anti-PD-1, lenalidomide, and azacitidine for PTCL
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Suzhou, JiangsuAges 18 years+ - NCT06947967RecruitingPhase 3
Tucidinostat plus CHOP for newly diagnosed PTCL-TFH lymphoma
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–80 - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07750886Recruiting
Collecting samples for lymphoma research
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Austin, TexasAges 18 years+ - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT06495723RecruitingPhase 1/Phase 2
Antibody therapy for relapsed T-cell lymphoma
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
CaenAges 18 years+ - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT06765564Recruiting
Study of stem cell therapy for amyotrophic lateral sclerosis (ALS) progression
This study tests whether a new treatment using special motor neuron cells made from stem cells (iPSCs) can help people with ALS. The cells will be transplanted into the spinal cord to try to slow the disease and improve function.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT05347524Recruiting
Blood test study to detect stomach cancer spread in the belly
This study checks whether a blood liquid biopsy test can detect when stomach cancer has spread to the lining of the abdomen (peritoneal metastasis). It compares people with confirmed belly spread to people whose belly lining tests were negative, using blood samples before/around treatment decisions.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80
Hear when a new Peripheral Blood Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral blood stem cell transplantation?
- Yes. Clin2 currently lists 173 recruiting peripheral blood stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral blood stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral blood stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.